Akebia Therapeutics, Inc. (AKBA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 50M 100M 150M Q3 '16: 0 Q4 '16: 1.5M Q1 '17: 20.9M Q2 '17: 28.5M Q3 '17: 41.3M Q4 '17: 90.6M Q1 '18: 45.9M Q2 '18: 48.8M Q3 '18: 53.2M Q4 '18: 59.9M Q1 '19: 72.7M Q2 '19: 100.8M Q3 '19: 92M Q4 '19: 69.6M Q1 '20: 88.5M Q2 '20: 90.1M Q3 '20: 60M Q4 '20: 56M Q1 '21: 52.3M Q2 '21: 52.9M Q3 '21: 48.8M Q4 '21: 57.7M Q1 '22: 61.7M Q2 '22: 126.4M Q3 '22: 48.7M Q4 '22: 55.8M Q1 '23: 40M Q2 '23: 56.4M Q3 '23: 42M Q4 '23: 56.2M Q1 '24: 32.6M Q2 '24: 43.6M Q3 '24: 37.4M Q4 '24: 46.5M Q1 '25: 57.3M Q2 '25: 62.5M Q3 '25: 58.8M Q4 '25: 57.6M Q1 '26: 53.5M Q2 '26: 49.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

-120M -80M -40M 0 40M 80M 120M Q4 '18: 52.1M Q1 '19: 41.4M Q2 '19: 63.1M Q3 '19: 53.7M Q4 '19: 31.4M Q1 '20: 60.8M Q2 '20: -84.5M Q3 '20: 29.6M Q4 '20: -7.2M Q1 '21: 17.7M Q2 '21: 418K Q3 '21: 32.8M Q4 '21: 10.1M Q1 '22: 30.4M Q2 '22: 107.8M Q3 '22: 10.4M Q4 '22: 52.4M Q1 '23: 19.8M Q2 '23: 39.1M Q3 '23: 24M Q4 '23: 37.5M Q1 '24: 21M Q2 '24: 26.6M Q3 '24: 23.3M Q4 '24: 26.1M Q1 '25: 49.7M Q2 '25: 52.6M Q3 '25: 49.4M Q4 '25: 45.1M Q1 '26: 41.3M Q2 '26: 38.7M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-180M -120M -60M 0 60M 120M 180M Q2 '16: -36.2M Q3 '16: -36.2M Q4 '16: -38M Q1 '17: -45M Q2 '17: -22.1M Q3 '17: -24.2M Q4 '17: 14.6M Q1 '18: -24.5M Q2 '18: -35.7M Q3 '18: -27.8M Q4 '18: -90.2M Q1 '19: -76M Q2 '19: -59.5M Q3 '19: -55.9M Q4 '19: -94.9M Q1 '20: -59.1M Q2 '20: -173.8M Q3 '20: -58.1M Q4 '20: -85.4M Q1 '21: -64.9M Q2 '21: -79.3M Q3 '21: -54.9M Q4 '21: -65.3M Q1 '22: -59.6M Q2 '22: 34.1M Q3 '22: -50.4M Q4 '22: -4.9M Q1 '23: -25.6M Q2 '23: -9M Q3 '23: -13M Q4 '23: 1.4M Q1 '24: -14.9M Q2 '24: -8.7M Q3 '24: -12.5M Q4 '24: -14.3M Q1 '25: 13.5M Q2 '25: 14.1M Q3 '25: 4.4M Q1 '26: -4.7M Q2 '26: -6.3M Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q4 '24 Q2 '26

Net Income Quarterly

-180M -120M -60M 0 60M 120M 180M Q2 '16: -35.8M Q3 '16: -36.3M Q4 '16: -37.9M Q1 '17: -44.5M Q2 '17: -21.5M Q3 '17: -23.1M Q4 '17: 15.5M Q1 '18: -23.4M Q2 '18: -34.1M Q3 '18: -26M Q4 '18: -60.1M Q1 '19: -72.4M Q2 '19: -58.2M Q3 '19: -54.6M Q4 '19: -94.5M Q1 '20: -60.7M Q2 '20: -175.8M Q3 '20: -60M Q4 '20: -87M Q1 '21: -69.6M Q2 '21: -83M Q3 '21: -59.5M Q4 '21: -69.9M Q1 '22: -63.5M Q2 '22: 29.4M Q3 '22: -54.1M Q4 '22: -6.1M Q1 '23: -26.9M Q2 '23: -11.2M Q3 '23: -14.5M Q4 '23: 614K Q1 '24: -18M Q2 '24: -8.6M Q3 '24: -20M Q4 '24: -22.8M Q1 '25: 6.1M Q2 '25: 247K Q3 '25: 540K Q1 '26: -9.1M Q2 '26: -8.9M Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q4 '24 Q2 '26

Cost of Revenue Quarterly

-60M 0 60M 120M 180M Q4 '18: 7.8M Q1 '19: 31.3M Q2 '19: 37.7M Q3 '19: 38.3M Q4 '19: 38.1M Q1 '20: 27.7M Q2 '20: 174.6M Q3 '20: 30.3M Q4 '20: 63.2M Q1 '21: 34.6M Q2 '21: 52.5M Q3 '21: 15.9M Q4 '21: 47.6M Q1 '22: 31.3M Q2 '22: 18.6M Q3 '22: 38.3M Q4 '22: -3.4M Q1 '23: 20.2M Q2 '23: 17.3M Q3 '23: 18M Q4 '23: 18.7M Q1 '24: 11.6M Q2 '24: 17M Q3 '24: 14.2M Q4 '24: 20.4M Q1 '25: 7.6M Q2 '25: 9.9M Q3 '25: 9.4M Q4 '25: 12.5M Q1 '26: 12.3M Q2 '26: 10.4M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '16: -28.2M Q4 '16: 95.7M Q1 '17: -9.5M Q2 '17: 24.4M Q3 '17: -54.6M Q4 '17: -16.4M Q1 '18: -20.3M Q2 '18: 9M Q3 '18: -12.5M Q4 '18: -73.7M Q1 '19: -137.9M Q2 '19: -38.4M Q3 '19: 11M Q4 '19: -92.1M Q1 '20: -89.6M Q2 '20: 37.2M Q3 '20: -27.2M Q4 '20: -30.8M Q1 '21: -70.7M Q2 '21: -63.1M Q3 '21: -56.3M Q4 '21: -62.8M Q1 '22: -21.6M Q2 '22: -30.7M Q3 '22: 33.8M Q4 '22: -54.7M Q1 '23: -17.5M Q2 '23: 3.6M Q3 '23: -7.2M Q4 '23: -2.3M Q1 '24: -19.4M Q2 '24: -10.1M Q3 '24: -6.7M Q4 '24: -4.5M Q1 '25: -13.6M Q2 '25: 22.3M Q3 '25: 28.1M Q4 '25: 31.1M Q1 '26: -21.2M Q2 '26: 3.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '16: -29.5M Q4 '16: 95.6M Q1 '17: -10M Q2 '17: 24.2M Q3 '17: -55.2M Q4 '17: -16.8M Q1 '18: -20.6M Q2 '18: 8.8M Q3 '18: -12.8M Q4 '18: -74.5M Q1 '19: -139.9M Q2 '19: -40.3M Q3 '19: 8.5M Q4 '19: -92.4M Q1 '20: -89.6M Q2 '20: 37.2M Q3 '20: -27.3M Q4 '20: -31.1M Q1 '21: -70.8M Q2 '21: -63.1M Q3 '21: -56.3M Q4 '21: -62.8M Q1 '22: -21.7M Q2 '22: -30.7M Q3 '22: 33.8M Q4 '22: -54.7M Q1 '23: -17.5M Q2 '23: 3.6M Q3 '23: -7.2M Q4 '23: -2.3M Q1 '24: -19.4M Q2 '24: -10.1M Q3 '24: -6.7M Q4 '24: -4.5M Q1 '25: -13.6M Q2 '25: 22.2M Q3 '25: 28M Q4 '25: 31.1M Q1 '26: -21.3M Q2 '26: 2.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 100M 200M 300M Q1 '17: 38.8M Q2 '17: 40.8M Q3 '17: 46.9M Q4 '17: 49.7M Q3 '20: 143.3M Q1 '21: 153.8M Q2 '21: 161.3M Q3 '21: 173.8M Q1 '22: 179.6M Q2 '22: 190.4M Q3 '22: 183.9M Q1 '23: 184.8M Q2 '23: 186.8M Q3 '23: 188.3M Q1 '24: 205M Q2 '24: 209.7M Q3 '24: 210.3M Q1 '25: 241.6M Q2 '25: 271.1M Q3 '25: 274.4M Q1 '26: 267M Q2 '26: 269.6M Q1 '17 Q4 '17 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '16: -3.27 Q4 '16: -3.60 Q1 '17: -4.05 Q2 '17: -3.63 Q3 '17: -3.16 Q4 '17: -1.86 Q1 '18: -1.19 Q2 '18: -1.26 Q3 '18: -1.23 Q4 '18: -2.41 Q1 '19: -2.55 Q2 '19: -2.44 Q3 '19: -2.44 Q4 '19: -2.36 Q1 '20: -2.21 Q2 '20: -3.00 Q3 '20: -2.96 Q4 '20: -2.77 Q1 '21: -2.75 Q2 '21: -1.98 Q3 '21: -1.90 Q4 '21: -1.70 Q1 '22: -1.60 Q2 '22: -0.94 Q3 '22: -0.89 Q4 '22: -0.53 Q1 '23: -0.33 Q2 '23: -0.54 Q3 '23: -0.33 Q4 '23: -0.29 Q1 '24: -0.23 Q2 '24: -0.21 Q3 '24: -0.23 Q4 '24: -0.34 Q1 '25: -0.22 Q2 '25: -0.18 Q3 '25: -0.08 Q4 '25: -0.02 Q1 '26: -0.08 Q2 '26: -0.11 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.